Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.55 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152990 | 1.00 | LMNA (0.62) | LMNAALDH1A1SMN1; SMN2DHODHHTT | |
| SCHEMBL14335627 | 0.82 | HTT (0.63) | LMNAALDH1A1HTTTAS1R3TAS1R1 | |
| SCHEMBL24066876 | 0.78 | EPHX1 (0.59) | LMNAALDH1A1HTTTAS1R3TAS1R1 | |
| SCHEMBL24066851 | 0.78 | EPHX1 (0.59) | LMNAALDH1A1HTTTAS1R3TAS1R1 | |
| SCHEMBL13569354 | 0.77 | HTT (0.64) | LMNAALDH1A1SMN1; SMN2HTTTAS1R3 | |
| SCHEMBL606392 | 0.77 | HTT (0.63) | LMNAALDH1A1SMN1; SMN2HTTTAS1R3 | |
| SCHEMBL15006999 | 0.77 | HTT (0.63) | LMNAALDH1A1SMN1; SMN2HTTTAS1R3 | |
| SCHEMBL1266129 | 0.77 | HTT (0.63) | LMNAALDH1A1SMN1; SMN2HTTTAS1R3 | |
| SCHEMBL6445345 | 0.75 | HTT (0.68) | LMNAALDH1A1HTTTAS1R3TAS1R1 | |
| SCHEMBL8340594 | 0.75 | HTT (0.68) | LMNAALDH1A1HTTTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD3B1 | LMNA 2353/4885ALDH1A1 82/4885SMN1; SMN2 2637/4885 |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD3B1 | LMNA 2353/4885ALDH1A1 82/4885SMN1; SMN2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.